surmount-1 trial tirzepatide non-diabetic weight loss (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants Tirzepatide for the Maintenance of
Description
How many weeks should I stay at my current 50-unit dose before increasing
After four weeks, the dose increases to 5 mg weekly
Masters, N
She skipped two entire dose escalation steps
If suspected, advise patients to promptly seek medical attention and discontinue ZEPBOUND
